Besides these several preclinical results, indicating a relationship between Met activation and radioresistance, the inhibitor crizotinib, in one study, failed to enhance the effect of radiation in head and neck squamous cell carcinoma xenografts [28], and clinical trials combining RT with Met inhibitors are so far lacking. Here, MET is linked to head and neck squamous cell carcinoma.